Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY RE-HIT: Ianalumab Re-treatment in ITP and wAIHA
NCT07039422Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Aug 2030
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ianalumab in primary immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), sponsored by Novartis. Planned start Jun 2026; status: withdrawn.
02
Drugs
ianalumab
03
Conditions
primary immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT07039422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07039422.